uniQure price target lowered to $35 from $38 at Chardan

Chardan lowered the firm’s price target on uniQure (QURE) to $35 from $38 and keeps a Buy rating on the shares after the company reported Q2 results. The company ended the quarter with cash and equivalents of $377M, supporting a projected operational runway into 2H27, the analyst tells investors in a research note. The firm also noted the company plans to present data in September from the ongoing Phase 1/2 studies of AMT-130 in support of a potential biologics license application submission, including three years of follow-up data for 24 treated patients.